United Therapeutics CEO Sells $5 Million Worth of Shares
On July 27, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NASDAQ: UTHR), sold 9,500 shares for a total value of $5 million under a pre-established Rule 10b5-1 trading plan adopted on November 7, 2025. The transaction involved the exercise of stock options at a strike price of $135.42 per share followed by an immediate sale at a weighted average price of $530.42. Rothblatt's remaining equity stake is valued at approximately $353.1 million, with most shares held indirectly through family trusts and other accounts. The CEO’s direct ownership remains unchanged at 40,513 shares, representing about 6% of the total post-transaction common stock interest. United Therapeutics has a market cap of $22 billion and reported trailing twelve-month revenue of $3.2 billion.
Tickers: $UTHR